DBDanny Bega

Danny Bega

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danny Bega has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Caffeine Use in Huntington’s Disease: A Single Center Survey

    by Jennifer Adrissi, Sarah Brooker, Alyssa McBride, Danielle Larson, Eric Gausche, Danny Bega

    Background: Anecdotal evidence suggests paradoxical caffeine overuse in individuals with Huntington’s disease (HD). A small retrospective study associated caffeine intake over 190 grams daily to earlier onset of HD symptoms. However, specific data on consumption habits is limited. This study aims to gather pilot data on caffeine use in people with HD, exploring motivations and consequences. Methods: Thirty adults with HD completed a survey on daily caffeine intake, its impact on symptoms, and consumption motivations through multiple-choice and open-ended questions. Descriptive statistics were used to analyze findings and compare them to general population data. Results: Caffeine intake ranged from 0 to 1400.4 mg/day, with a median of 273.2 mg/day and a mean of 382.5 mg/day. Seventy percent of participants with HD consumed more caffeine than the average for their age group in the general population. Additionally, 20% of participants and 38% of family members believed caffeine influenced HD symptoms, primarily anxiety. Discussion: People with HD typically consume more caffeine than the general U.S. population. Contrary to the hypothesis, higher caffeine intake was not associated with significant subjective worsening of HD symptoms. Further research with objective measures and multiple HD centers is necessary to guide screening and counseling on caffeine use in this population. Highlights Participants with Huntington’s disease (HD) had increased caffeine intake compared to the general population, supporting previous anecdotal observations. Anxiety was the most affected HD symptom. Further research using objective measures of symptom burden and including multiple HD centers can help inform screening and counseling regarding caffeine use in this population.


  • Open Access

    Medicinal Cannabis for Parkinson's Disease: Practices, Beliefs, and Attitudes Among Providers at National Parkinson Foundation Centers of Excellence

    by Danny Bega, Tanya Simuni, Michael S. Okun, Xinguang Chen, Peter Schmidt

    Background: Legalization of the medical use of cannabis for Parkinson's disease (PD) has bypassed the traditional drug‐approval process, leaving physicians with little evidence with which to guide patients.Objective: The goal of this study was to gather data on the cannabis‐related prescribing practices and views regarding potential risks and benefits of cannabis among experts caring for patients with PD.Methods: An anonymous, 73‐item online survey was conducted through an online service (SurveyMonkey) and included neurologists at all National Parkinson Foundation Centers of Excellence.Results: Fifty‐six responders represented centers across 5 countries and 14 states. 23% reported some formal education on cannabis. Eighty percent of responders had patients with PD who used cannabis, and 95% were asked to prescribe it. Fifty‐two percent took a neutral position on cannabis use with their patients, 9% discouraged use, and 39% encouraged it. Most believed that the literature supported use of cannabis for nausea (87%; n = 48), anxiety (60%; n = 33), and pain (86%; n = 47), but responses were divided with regard to motor symptoms. Most respondents expected that cannabis would worsen motivation (59%; n = 32), sleepiness (60%; n = 31), and hallucinations (69%; n = 37). In addition, most feared negative effects on short‐term memory (75%; n = 42), long‐term memory (55%; n = 31), executive functioning (79%; n = 44), and driving (96%; n = 54). Although many did not believe that cannabis should be recreational (50%; n = 28), most believed that it should be legalized for medicinal purposes (69.6%; n = 39).Conclusions: This study provides data on the cannabis‐related practices, beliefs, and attitudes of expert PD physicians. There is a lack of consensus that likely reflects a general knowledge gap and paucity of data to guide clinical practice.


  • Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 Cohort

    by Danny Bega, Soeun Kim, Yunxi Zhang, Jordan Elm, Jay Schneider, Robert Hauser, Andy Fraser, Tanya Simuni

    Background: Data on predictors of decline in PD are largely based on de-novo populations and limited to the use of motor outcomes that fail to capture the full scope of disease. Data on predictors of decline in PD are largely based on de-novo populat


  • Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease

    by Danny Bega, Sheng Luo, Hubert Fernandez, Kelvin Chou, Michael Aminoff, Sotirios Parashos, Harrison Walker, David S. Russell, Chadwick W. Christine, Rohit Dhall, et al.

    Background: Depression is one of the most common nonmotor symptoms associated with Parkinson's disease ( PD ), yet the impact of depression on progression of disease is unclear. Objective: The aim of this study was to prospectively characterize the relationship between depressive symptoms and measures of disease progression in a large sample of patients with early, medically treated PD . Methods: Baseline and longitudinal Beck Depression Inventory ( BDI ) scores from participants in the NINDS Exploratory Trials in PD Long Term Study 1 were correlated with changes in multiple measures of disease severity over 5 years. Multivariate analysis of predictors of change in BDI was performed. Results: Of 1,741 participants, 746 completed 5‐year assessments and were included. Mean age was 62.00 years (standard deviation [SD]: 9.22) and mean disease duration was 1.69 years ( SD, 1.16). Mean BDI score was 6.24 ( SD, 5.02) at baseline and 8.57 ( SD, 6.60) at 5 years. Baseline BDI score was strongly associated with rate of change in all examined measures of disease severity. In multivariate analysis, BDI 5‐year change was associated with change in UPDRS Part I (excluding depression item; P < 0.01), 33‐item Parkinson's Disease Questionnaire ( P < 0.01), EuroQOL Five Dimensional Questionnaire ( P = 0.02), and Total Functional Capacity ( P < 0.01), but was not associated with motor or cognitive measures. This model explained 68.8% of the variance 5‐year change of the BDI score. Conclusions: Worse baseline BDI scores are associated with a decline in multiple measures of disease severity in PD . Worsening of BDI at 5 years was associated with worsening in UPDRS Part I and quality‐of‐life measures, but not with motor or cognitive measures.


  • Open Access

    Complementary & Alternative Management of Parkinson’s Disease: An Evidence-Based Review of Eastern Influenced Practices

    by Danny Bega, Cindy Zadikoff

    The prevalence of Parkinson's disease (PD) appears to be lower in Asia compared to the Western world. It is unclear if this is related to the ubiquitous use of traditional medicine in Eastern healthcare, but the use of complementary and alternative medicine (CAM) modalities in countries like Korea may be as high as 76%. Among patients with PD, herbal medicines, health supplement foods, and acupuncture are interventions which are increasingly used throughout the world. Countries like Korea, China, India, and Japan have long embraced and incorporated traditional medicine into modern management of conditions such as PD, but research into various CAM modalities remains in its infancy limiting evidence-based recommendations for many treatments. We reviewed the literature on CAM treatments for PD, focusing on mind-body interventions and natural products. Based on evidence limited to randomized-controlled trials we found that mind-body interventions are generally effective forms of physical activity that are likely to foster good adherence and may reduce disability associated with PD. Based on the current data, modalities like Tai Chi and dance are safe and beneficial in PD, but better studies are needed to assess the effects of other frequently used modalities such as yoga and acupuncture. Furthermore, despite centuries of experience using medicinal herbs and plants in Eastern countries, and despite substantial preclinical data on the beneficial effects of nutritional antioxidants as neuroprotective agents in PD, there is insufficient clinical evidence that any vitamin, food additive, or supplement, can improve motor function or delay disease progression in PD.


  • A Review of the Clinical Evidence for Complementary and Alternative Therapies in Parkinson’s Disease

    by Danny Bega, Paulina Gonzalez-Latapi, Cindy Zadikoff, Tanya Simuni

    No conventional treatment has been convincingly demonstrated to slow or stop the progression of Parkinson’s disease (PD). Dopaminergic therapy is the gold standard for managing the motor disability associated with PD, but it falls short of managing all of the aspects of the disease that contribute to quality of life. Perhaps for this reason, an increasing number of patients are searching for a more holistic approach to healthcare. This is not to say that they are abandoning the standard and effective symptomatic therapies for PD, but rather are complementing them with healthy living, mind-body practices, and natural products that empower patients to be active participants in their healthcare and widen the net under which disease modification might one day be achieved. Despite high rates of utilization of complementary and alternative medicine (CAM) practices, data on efficacy is generally limited, restricting physicians in providing guidance to interested patients. Exercise is now well-established as integral in the management of PD, but mind-body interventions such as Tai Chi that incorporate relaxation and mindfulness with physical activity should be routinely encouraged as well. While no comment can be made about neuroplastic or disease-modifying effects of mind-body interventions, patients should be encouraged to be as active as possible and engage with others in enjoyable and challenging activities such as dance, music therapy, and yoga. Many PD patients also choose to try herbs, vitamins, and neutraceuticals as part of a healthy lifestyle, with the added expectation that these products may lower free radical damage and protect them against further cell death. Evidence for neuroprotection is limited, but patients can be encouraged to maintain a healthy diet rich in “high-power,” low-inflammatory foods, while at the same time receiving education that many promising natural products have produced disappointing results in clinical trials. It is vital that the science of holistic medicine reaches a point where all neutraceuticals are investigated with the same rigor as conventional drugs. A number of agents discussed here that have a proposed role in the treatment of neurodegenerative diseases (and PD in particular), including cannabis, mucuna pruriens, and Chinese herbals, deserve more attention from basic science researchers and clinical investigators before they can be either safely utilized or dismissed.


  • Open Access

    Recognition and Treatment of Depressive Symptoms in Parkinson's Disease: The NPF Dataset

    by Danny Bega, Sam S. Wu, Qinglin Pei, Peter N. Schmidt, Tanya Simuni

    Depression is a major determinant of Health Related Quality of Life in PD, but there is limited data on physician recognition of depression and treatment efficacy. We used data obtained from the QII dataset of the National Parkinson's Foundation data